Jubilant Pharmova Limited has announced the appointment of Daniel J. O’Connor as the CEO of its Proprietary Novel drugs business, Jubilant Therapeutics Inc. With over 30 years of leadership in biotechnology and oncology, O’Connor’s experience includes his recent role as CEO of Ambrx Biopharma, culminating in a successful acquisition. His expertise is expected to drive innovation in cancer therapies.
Leadership Change at Jubilant Therapeutics
Daniel J. O’Connor has been appointed as the new CEO of Jubilant Therapeutics Inc., a step-down subsidiary of Jubilant Pharmova Limited. The announcement was made on December 2, 2025, signaling a strategic move to strengthen the company’s focus on novel drug development.
O’Connor’s Background
O’Connor brings over 30 years of experience in the biotechnology and oncology sectors. His previous role as CEO of Ambrx Biopharma saw a significant increase in the company’s valuation, leading to its successful acquisition. He also played a vital role at ImClone Systems, contributing to the development and launch of a major oncology therapy. Additionally, he served as CEO of Advaxis, transforming it into a late-stage clinical enterprise.
Strategic Focus
The appointment of O’Connor aligns with Jubilant Pharmova’s mission to build a clinical-stage therapeutics company focused on developing innovative therapies for various cancer indications. Shyam S. Bhartia, Chairman, and Hari S. Bhartia, Co-Chairman, expressed their enthusiasm for O’Connor joining the team.
Jubilant Therapeutics’ Pipeline
Jubilant Therapeutics Inc. is focused on developing precision oral medicines for oncology and autoimmune diseases. Their pipeline includes JBI-802, a dual COREST modifier in Phase I/II clinical trials, and a novel brain-penetrant modulator of PRMT5, also in Phase I clinical trial. The company is based in Pennsylvania and guided by globally renowned scientific advisors.
Source: BSE